Market Cap 1.26B
Revenue (ttm) 23.68M
Net Income (ttm) -318.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,346.11%
Debt to Equity Ratio 2.18
Volume 14,941,400
Avg Vol 2,502,820
Day's Range N/A - N/A
Shares Out 86.14M
Stochastic %K 17%
Beta 0.68
Analysts Strong Sell
Price Target $37.69

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 419 1400
Website: syndax.com
Address:
730 Third Avenue, 9th Floor, New York, United States
cchronobreak
cchronobreak Oct. 25 at 10:31 AM
0 · Reply
CH_Expat
CH_Expat Oct. 25 at 8:18 AM
$SNDX Who sold CTIC back then? And who is our CEO? The new arrival for the BOD has a history at which company we shares profits with for which drug? Connect the dots. Ignore the idiots.
0 · Reply
CH_Expat
CH_Expat Oct. 25 at 8:14 AM
$SNDX One of my preferred setups for substantial wins is this here. Selloff on good or no news with high institutional ownership. Nothing but manipulation to suck up more shares for the whales. Starter here and double every 10% down. Ignore idiots, stick to fundamentals. EV 600m for a drug that has, all weaknesses aside easily 1 billion dollar peak sales. Is this fair value at 1.2b MC? I say no.
1 · Reply
CH_Expat
CH_Expat Oct. 25 at 7:37 AM
$SNDX Approval shakeout, seen so many times. Ignore fudsters, opening positions at this price bring you profits in a foreseeable future.
1 · Reply
urthousk
urthousk Oct. 25 at 6:22 AM
$NVDA $TSLA $SNDX $INOD ;; https://stocktwits.com/urthousk/message/633694291
0 · Reply
LongLongStock
LongLongStock Oct. 25 at 6:08 AM
$SNDX i think stock usually goes down on pdufa, but if this stock is heavily own by institutions, and management executes, this could 3x to 6x within the next year
0 · Reply
Candycaneispeppermint
Candycaneispeppermint Oct. 25 at 5:35 AM
$SNDX ? It was always Kura that wins this market. The FDA has spoken.
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 25 at 3:53 AM
I'm not the one to trade based on momentum, will buy $SNDX when H% is low like I did here
1 · Reply
Habanacuba
Habanacuba Oct. 25 at 3:44 AM
$SNDX Don't you think that starting next week some analysts will raise their PT?
0 · Reply
FreddieMercury91
FreddieMercury91 Oct. 25 at 3:33 AM
$SNDX all going to lose all our money
0 · Reply
Latest News on SNDX
3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 9 days ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY INCY XBI


Making Money In Biotech Stocks

Oct 9, 2025, 5:00 PM EDT - 15 days ago

Making Money In Biotech Stocks

GERN


3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 5 weeks ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS TVTX


Syndax Announces Participation in September Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Syndax Announces Participation in September Investor Conferences


Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Aug 13, 2025, 6:34 PM EDT - 2 months ago

Syndax Pharmaceuticals: A Tale Of Two Drug Launches


Syndax Pharmaceuticals: The Story Brightens

Aug 5, 2025, 12:59 PM EDT - 2 months ago

Syndax Pharmaceuticals: The Story Brightens


Syndax Announces Participation in June Investor Conferences

May 29, 2025, 7:00 AM EDT - 5 months ago

Syndax Announces Participation in June Investor Conferences


Syndax Announces Participation in May Investor Conferences

May 8, 2025, 7:00 AM EDT - 6 months ago

Syndax Announces Participation in May Investor Conferences


Syndax Announces Participation in March Investor Conferences

Feb 25, 2025, 7:00 AM EST - 8 months ago

Syndax Announces Participation in March Investor Conferences


Syndax Announces Participation in February Investor Conferences

Jan 30, 2025, 7:00 AM EST - 9 months ago

Syndax Announces Participation in February Investor Conferences


US FDA approves Syndax's blood cancer drug

Nov 15, 2024, 6:26 PM EST - 1 year ago

US FDA approves Syndax's blood cancer drug


cchronobreak
cchronobreak Oct. 25 at 10:31 AM
0 · Reply
CH_Expat
CH_Expat Oct. 25 at 8:18 AM
$SNDX Who sold CTIC back then? And who is our CEO? The new arrival for the BOD has a history at which company we shares profits with for which drug? Connect the dots. Ignore the idiots.
0 · Reply
CH_Expat
CH_Expat Oct. 25 at 8:14 AM
$SNDX One of my preferred setups for substantial wins is this here. Selloff on good or no news with high institutional ownership. Nothing but manipulation to suck up more shares for the whales. Starter here and double every 10% down. Ignore idiots, stick to fundamentals. EV 600m for a drug that has, all weaknesses aside easily 1 billion dollar peak sales. Is this fair value at 1.2b MC? I say no.
1 · Reply
CH_Expat
CH_Expat Oct. 25 at 7:37 AM
$SNDX Approval shakeout, seen so many times. Ignore fudsters, opening positions at this price bring you profits in a foreseeable future.
1 · Reply
urthousk
urthousk Oct. 25 at 6:22 AM
$NVDA $TSLA $SNDX $INOD ;; https://stocktwits.com/urthousk/message/633694291
0 · Reply
LongLongStock
LongLongStock Oct. 25 at 6:08 AM
$SNDX i think stock usually goes down on pdufa, but if this stock is heavily own by institutions, and management executes, this could 3x to 6x within the next year
0 · Reply
Candycaneispeppermint
Candycaneispeppermint Oct. 25 at 5:35 AM
$SNDX ? It was always Kura that wins this market. The FDA has spoken.
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 25 at 3:53 AM
I'm not the one to trade based on momentum, will buy $SNDX when H% is low like I did here
1 · Reply
Habanacuba
Habanacuba Oct. 25 at 3:44 AM
$SNDX Don't you think that starting next week some analysts will raise their PT?
0 · Reply
FreddieMercury91
FreddieMercury91 Oct. 25 at 3:33 AM
$SNDX all going to lose all our money
0 · Reply
BrunetteSara
BrunetteSara Oct. 25 at 3:14 AM
0 · Reply
Jabed206
Jabed206 Oct. 25 at 2:45 AM
1 · Reply
DorisgtBoone
DorisgtBoone Oct. 25 at 2:16 AM
#CVKD Exciting news: Cadrenal Therapeutics Company Webcast @ Lytham Partners Fall 2025 Investor Conference. Watch live here: https://youtu.be/NfPbBjgeIbg?si=2xPvJ2_YJQjHipGa $SNDX
0 · Reply
DLAT94
DLAT94 Oct. 25 at 1:59 AM
$SNDX Well, this didn’t go exactly according to plan. If there had been a run-up beforehand, I’d understand the sell-off after the PDUFA announcement, but without a run-up? Nevertheless, I remain extremely confident in this company and its two drugs for the foreseeable future (at least until the combo studies arrive). Since I missed the party after the trading halt yesterday, I’m hoping to be able to add significantly to my position at the current lower price. Goal: 16k shares, average $11. Expect this to get to at least 2b+ market cap. Glta.
2 · Reply
sfb_26
sfb_26 Oct. 25 at 1:57 AM
$SNDX The recent candle closed near the low of day momentum still to the downside. However, oversold RSI + volume climax suggests we’re near a potential short-term exhaustion point.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 1:49 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SNDX Current Share Price: $14.92 Contracts: $SNDX January 15, 2027 $15 Calls Scale in: $4.45- $5.44 Scale out: $6.93-$8.91 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Habanacuba
Habanacuba Oct. 25 at 1:31 AM
$SNDX If the drug were as bad as some shorts say, why did the FDA approve it?
0 · Reply
SnoopDawg
SnoopDawg Oct. 25 at 1:25 AM
$SNDX everyone posting why to hold ... why its so good... just sell. Sooner the mms get their stock the sooner the rest of us ride.
0 · Reply
dgbio
dgbio Oct. 24 at 11:45 PM
$SNDX Kura has traded lower efficacy for better safety. Revu vs zifto: ORR, 47% vs 33%, median OS in responders, 23 month vs 18 month, transplants, 11% vs 2%. Revu's discontinuation rate is only about 5% and even these 5% are matched by the pediatric market (about 6% of NPM1) which only Syndax has. Kura is going to have an uphill battle to win an equal share in NPM1, while the KM2TAr market is for Syndax only.
1 · Reply
Brokester
Brokester Oct. 24 at 11:20 PM
1 · Reply
cchronobreak
cchronobreak Oct. 24 at 11:01 PM
0 · Reply
Ronasongs
Ronasongs Oct. 24 at 10:37 PM
$SNDX Learning lesson to myself. When a stock is shorted nearly 30% by the MM's, they will get their money. Im holding, averaged down.
0 · Reply